Targeting the endocannabinoid system to treat anxiety-related disorders

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 27, Issue 3, 2016, Pages 193-202

  Korem, Nachshon ^a   Zer Aviv, Tomer Mizrachi ^a   Ganon Elazar, Eti ^a   Abush, Hila ^a   Akirav, Irit ^a  

^a UNIVERSITY OF HAIFA   (Israel)

Author keywords

anxiety related disorders; cannabinoids; endocannabinoid system; post traumatic stress disorder (PTSD)

Indexed keywords

ENDOCANNABINOID; CANNABINOID;

ANXIETY DISORDER; FEAR; HUMAN; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; REVIEW; ANIMAL; ANXIETY; METABOLISM; STRESS DISORDERS, POST-TRAUMATIC;

ANIMALS; ANXIETY; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84969804094     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/jbcpp-2015-0058     Document Type: Review

References (97)

1. Abush H, Akirav I. Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory. Neuropsychopharmacology 2013;38:1521-34.
2. Fattore L, Fadda P, Spano MS, Pistis M, Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008;286:S97-107.
3. Ganon-Elazar E, Akirav I. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J Neurosci 2009;29:11078-88.
4. Ganon-Elazar E, Akirav I. Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress. Neuropsychopharmacology 2012;37:456-66.
5. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418:530-4.
6. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013;18:1034-40.
7. Steiner MA, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008;170:397-432.
8. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005;81:331-42.
9. Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008;32:1152-60.
10. Kessler RC, Ormel J, Petukhova M, McLaughlin KA, Green JG, Russo LJ, et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry 2011;68:90-100.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
12. Norrholm SD, Ressler KJ. Genetics of anxiety and trauma-related disorders. Neuroscience 2009;164:272-87.
13. Pillay NS, Stein DJ. Emerging anxiolytics. Expert Opin Emerg Drugs 2007;12:541-5.
14. Zhang W, Davidson JR. Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. Expert Opin Pharmacother 2007;8:1861-70.
15. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
16. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
17. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003;83:1017-66.
18. Kogan NM, Mechoulam R. The chemistry of endocannabinoids. J Endocrinol Invest 2006;29:3-14.
19. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008;160:1-24.
20. Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry 2009;21:113-21.
21. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-83.
22. Pazos MR, Nunez E, Benito C, Tolon RM, Romero J. Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 2005;81:239-47.
23. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review. Pharmacol Biochem Behav 2008;90:501-11.
24. Morena M, Campolongo P. The endocannabinoid system: an emotional buffer in the modulation of memory function. Neurobiol Learn Mem 2014;112:30-43.
25. Zanettini C, Panlilio LV, Aliczki M, Goldberg SR, Haller J, Yasar S. Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 2011;5:57.
26. Hill MN, Gorzalka BB. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 2009;8:451-8.
27. Lafentre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 2007;56:367-81.
28. Haller J, Barna I, Barsvari B, Pelczer KG, Yasar S, Panlilio LV, et al. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 2009;204:607-16.
29. Simone JJ, Green MR, Hodges TE, McCormick CM. Differential effects of CB1 receptor agonism in behavioural tests of unconditioned and conditioned fear in adult male rats. Behav Brain Res 2015;279:9-16.
30. Zovkic IB, Sweatt JD. Epigenetic mechanisms in learned fear: implications for PTSD. Neuropsychopharmacology 2013;38: 77-93.
31. Pamplona FA, Takahashi RN. WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci Lett 2006;397:88-92.
32. Atsak P, Roozendaal B, Campolongo P. Role of the endocannabinoid system in regulating glucocorticoid effects on memory for emotional experiences. Neuroscience 2012;204:104-16.
33. Mishima K, Egashira N, Hirosawa N, Fujii M, Matsumoto Y, Iwasaki K, et al. Characteristics of learning and memory impairment induced by delta9-tetrahydrocannabinol in rats. Jpn J Pharmacol 2001;87:297-308.
34. Nasehi M, Piri M, Jamali-Raeufy N, Zarrindast MR. Influence of intracerebral administration of NO agents in dorsal hippocampus (CA1) on cannabinoid state-dependent memory in the stepdown passive avoidance test. Physiol Behav 2010;100:297-304.
35. Abush H, Akirav I. Cannabinoids modulate hippocampal memory and plasticity. Hippocampus 2010;20:1126-38.
36. Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, McGaugh JL, et al. Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci USA 2009;106:4888-93.
37. Hauer D, Ratano P, Morena M, Scaccianoce S, Briegel I, Palmery M, et al. Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology 2011;114:1380-8.
38. Morena M, Roozendaal B, Trezza V, Ratano P, Peloso A, Hauer D, et al. Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training. Proc Natl Acad Sci USA 2014;111:18333-8.
39. Llorente-Berzal A, Terzian AL, di Marzo V, Micale V, Viveros MP, Wotjak CT. 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. Psychopharmacology (Berl) 2015;232:2811-25.
40. Lemos JI, Resstel LB, Guimaraes FS. Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. Behav Brain Res 2010;207:105-11.
41. Fogaca MV, Reis F, Campos AC, Guimaraes FS. Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT 1A receptors and previous stressful experience. Eur Neuropsychopharmacol 2014;24:410-9.
42. Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C, et al. Classical fear conditioning in the anxiety disorders: a meta-analysis. Behav Res Ther 2005;43:1391-424.
43. Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol Psychiatry 2007;62:446-54.
44. Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther 2014;149:150-90.
45. Bitencourt RM, Pamplona FA, Takahashi RN. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 2008;18:849-59.
46. Chhatwal JP, Myers KM, Ressler KJ, Davis M. Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J Neurosci 2005;25:502-6.
47. Pamplona FA, Bitencourt RM, Takahashi RN. Short- and longterm effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem 2008;90:290-3.
48. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 2013;34:637-44.
49. De Oliveira Alvares L, Genro BP, Diehl F, Molina VA, Quillfeldt JA. Opposite action of hippocampal CB1 receptors in memory reconsolidation and extinction. Neuroscience 2008;154:1648-55.
50. Lin HC, Mao SC, Su CL, Gean PW. The role of prefrontal cortex CB1 receptors in the modulation of fear memory. Cereb Cortex 2009;19:165.
51. Do Monte FH, Souza RR, Bitencourt RM, Kroon JA, Takahashi RN. Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors. Behav Brain Res 2013;250:23-7.
52. Trouche S, Sasaki JM, Tu T, Reijmers LG. Fear extinction causes target-specific remodeling of perisomatic inhibitory synapses. Neuron 2013;80:1054-65.
53. Gray RM, Liotta RF. PTSD: extinction, reconsolidation, and the visual-kinesthetic dissociation protocol. Traumatology 2012;18:3-16.
54. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS. Functional interactions between stress and the endocannabi noid system: from synaptic signaling to behavioral output. J Neurosci 2010;30:14980-6.
55. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol 2007;36:92-101.
56. Ramikie TS, Patel S. Endocannabinoid signaling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stress. Neuroscience 2012;204:38-52.
57. Riebe CJ, Pamplona F, Kamprath K, Wotjak CT. Fear relief - toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 2012;204:159-85.
58. Liberzon I, Krstov M, Young EA. Stress-restress: effects on ACTH and fast feedback. Psychoneuroendocrinology 1997;22:443-53.
59. Kohda K, Harada K, Kato K, Hoshino A, Motohashi J, Yamaji T, et al. Glucocorticoid receptor activation is involved in producing abnormal phenotypes of single-prolonged stress rats: a putative post-traumatic stress disorder model. Neuroscience 2007;148:22-33.
60. Ganon-Elazar E, Akirav I. Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit. Psychoneuroendocrinology 2013;38:1675-87.
61. Scrimin S, Moscardino U, Capello F, Altoe G, Steinberg AM, Pynoos RS. Trauma reminders and PTSD symptoms in children three years after a terrorist attack in Beslan. Soc Sci Med 2011;72:694-700.
62. Layne CM, Olsen JA, Baker A, Legerski JP, Isakson B, Pašali A, et al. Unpacking trauma exposure risk factors and differential pathways of influence: predicting postwar mental distress in Bosnian adolescents. Child Dev 2010;81:1053-76.
63. Pynoos RS, Ritzmann RF, Steinberg AM, Goenjian A, Prisecaru I. A behavioral animal model of posttraumatic stress disorder featuring repeated exposure to situational reminders. Biol Psychiatry 1996;39:129-34.
64. Louvart H, Maccari S, Ducrocq F, Thomas P, Darnaudery M. Longterm behavioural alterations in female rats after a single intense footshock followed by situational reminders. Psychoneuroendocrinology 2005;30:316-24.
65. Siegmund A, Wotjak CT. A mouse model of posttraumatic stress disorder that distinguishes between conditioned and sensitised fear. J Psychiatr Res 2007;41:848-60.
66. Korem N, Akirav I. Cannabinoids prevent the effects of a footshock followed by situational reminders on emotional processing. Neuropsychopharmacology 2014;39:2709-22.
67. Campos AC, Ferreira FR, da Silva WA, Guimaraes FS. Predator threat stress promotes long lasting anxiety-like behaviors and modulates synaptophysin and CB1 receptors expression in brain areas associated with PTSD symptoms. Neurosci Lett 2013;533:34-8.
68. Mayer TA, Matar MA, Kaplan Z, Zohar J, Cohen H. Blunting of the HPA-axis underlies the lack of preventive efficacy of early post-stressor single-dose Delta-9-tetrahydrocannabinol (THC). Pharmacol Biochem Behav 2014;122:307-18.
69. Hsiao Y-T, Yi P-L, Li C-L, Chang F-C. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology 2012;62:373-84.
70. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2007;12:120-50.
71. Rabinak CA, Angstadt M, Lyons M, Mori S, Milad MR, Liberzon I, et al. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem 2014;113:125-34.
72. Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) 2013;226:781-92.
73. Klumpers F, Denys D, Kenemans JL, Grillon C, van der Aart J, Baas JM. Testing the effects of 9-THC and D-cycloserine on extinction of conditioned fear in humans. J Psychopharmacol (Oxf) 2012;26:471-8.
74. Gorka SM, Fitzgerald DA, de Wit H, Phan KL. Cannabinoid modulation of amygdala subregion functional connectivity to social signals of threat. Int J Neuropsychopharmacol 2014;18:pyu104.
75. Hauer D, Schelling G, Gola H, Campolongo P, Morath J, Roozendaal B, et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One 2013;8:e62741.
76. Fraser GA. The use of a synthetic cannabinoid in the management of treatmentresistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009;15:84-8.
77. Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981;21:377S-82S.
78. Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral 9- tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 2014;34:587-91.
79. Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic eventexposed marijuana users. J Trauma Stress 2007;20:577-86.
80. Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav 2011;25:554-8.
81. Hirvonen J, Goodwin RS, Li C-T, Terry GE, Zoghbi SS, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012;17:642-9.
82. Klugmann M, Klippenstein V, Leweke FM, Spanagel R, Schneider M. Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels. Int J Neuropsychopharmacol 2011;14:505-17.
83. Neumeister A. The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD. Depress Anxiety 2013;30:93-6.
84. Le Foll B, Tyndale RF. Cannabinoids: friend or foe? Clin Pharmacol Ther 2015;97:528-31.
85. Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. In: Pertwee RR, editor. Cannabinoids. Handbook of experimental pharmacology, Vol. 168. Heidelberg: Springer, 2005:117-45.
86. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:21-47.
87. Parolaro D, Realini N, Vigano D, Guidali C, Rubino T. The endocannabinoid system and psychiatric disorders. Exp Neurol 2010;224:3-14.
88. Campos AC, Guimaraes FS. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1517-21.
89. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol (Oxf) 1993;7:82-8.
90. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S, et al. Modulation of effective connectivity during emotional processing by 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010;13:421-32.
91. Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008;54:129-40.
92. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxietylike behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008;54:141-50.
93. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006;318:304-11.
94. Rubino T, Realini N, Guidali C, Braida D, Capurro V, Castiglioni C, et al. Chronic 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 2008;33:2760-71.
95. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 2011;124:250-61.
96. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc B Biol Sci 2012;367:3353-63.
97. Rabinak CA, Phan KL. Cannabinoid modulation of fear extinction brain circuits: a novel target to advance anxiety treatment. Curr Pharm Des 2014;20:2212-7.